ECE2018 Poster Presentations: Thyroid Thyroid (non-cancer) (105 abstracts)
Prevalence of thyroid dysfunction in Catalonia from two different registers: pharmaceutical delivery records and diagnostic records (EUthyroid project)
Sara Torrejón 1 , Berta Soldevila 2 , Montse Martín-Baranera 3 , Manel Puig-Domingo 4 , Inés Velasco 5 , Lluís Vila 6 & Thyroid Area of Spanish Society of Endocrinology and Nutrition 7
1Endocrinology and Nutrition Service, Hospital of Sant Joan Despí Moisès Boggi, Sant Hoan Despí (Barcelone), Spain; 2Endocrinology and Nutrition Service, Hopital of Germans Trias i Pujol, Badalona, Spain; 3Clinical Epidemiology Service, Consorci Sanitari Integral, Hospitalet del Llobegat, Spain; 4Germans Trias i Pujol, Research Institute, Badalona, Spain; 5Obstetrics and Gynecology Service, Hospital of Riotinto, Huelva, Spain; 6Endocrinology and Nutrition Service, Hospital of Sant Joan Despí Moisès Boggi, Sant Joan Despí (Barcelone), Spain. 7SEEN, Madrid, Spain.
Background: Cross-sectional studies performed to estimate the prevalence (Prev) of thyroid dysfunctions are expensive and involve a great effort. Diagnosis and therapeutic prescription records may be a good alternative to monitor such prevalence. They also allow to easily compare the thyroid dysfunctions prevalence of among different populations (EUthyroid Project).
Objective: 1) To estimate the Prev of hypothyroidism (hypoT) and hyperthyroidism (hyperT) based on Pharmaceutical Delivery records (PHDR) and on Diagnostic Records (DR) of the population of Catalonia; 2) To analyse the concordance of the results between both registers.
Methods: The population officially insured in the Public Health System (CatSalut) in 2014 was the basis for the calculations of the Prev. The information contained in the PHDR of the CatSalut on the number of DDD dispensed (HO3A: preparations of levothyroxine and HO3B: preparations of antithyroid medication) and the number of patients in treatment (NPT) was used. For the calculation of the prevalence based on the diagnoses, the “Minimum basic data set” registry of CatSalut was used, choosing the ICD-9 codes include 242 code for hyperT and in 244 and 243 codes for hypoT.
Results: The total of Catalan population insured in 2014 (from 0 to 108 years) was 7, 556 330 people. The global Prev of hypoT and hyperT based on NPT with levothyroxine or with antithyroid treatment was 3.07% and 0.14% respectively. The Prev of hypoT estimated by the registered codes 244+243 was 2.54%. The prev of hyperT based on the registered code 242 was 0.35%.
Conclusions: The Prev of hypoT is higher based on the PHDR than on the DR. The estimate of hyperT Prev is higher based on DR than on PHDR, probably because the subclinical hyperT is included in DR. Both the DR and the PHDR underestimate the Prev of both diagnoses (HypoT and HyperT) compared to cross-sectional studies of Spain and Catalonia. This discordance might be explained by the difficult record of subclinical dysfunction according to the ICD-9 (and also ICD-10).
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more